133 related articles for article (PubMed ID: 17526095)
1. New treatments for diabetes.
Irony I; Parks MH; Meyer RJ
N Engl J Med; 2007 May; 356(21):2221; author reply 2222-3. PubMed ID: 17526095
[No Abstract] [Full Text] [Related]
2. New treatments for diabetes.
Raz I; Eldor R
N Engl J Med; 2007 May; 356(21):2222; author reply 2222-3. PubMed ID: 17526096
[No Abstract] [Full Text] [Related]
3. New treatments for diabetes.
Mintz ML
N Engl J Med; 2007 May; 356(21):2221-2; author reply 2222-3. PubMed ID: 17526094
[No Abstract] [Full Text] [Related]
4. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
Musch A; Heinzl S
Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
[No Abstract] [Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Ahrén B
Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
[No Abstract] [Full Text] [Related]
6. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Heinzl S
Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
[No Abstract] [Full Text] [Related]
7. MK-431 (Merck).
Deacon CF
Curr Opin Investig Drugs; 2005 Apr; 6(4):419-26. PubMed ID: 15898349
[TBL] [Abstract][Full Text] [Related]
8. Finding new treatments for diabetes--how many, how fast... how good?
Nathan DM
N Engl J Med; 2007 Feb; 356(5):437-40. PubMed ID: 17267901
[No Abstract] [Full Text] [Related]
9. DPP-4 inhibitors. A new class of drugs for type 2 diabetes.
Marino MT
Diabetes Self Manag; 2008; 25(4):60, 62-4. PubMed ID: 18717028
[No Abstract] [Full Text] [Related]
10. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
11. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
12. Incretin mimetics vie for slice of type 2 diabetes market.
Shaffer C
Nat Biotechnol; 2007 Mar; 25(3):263. PubMed ID: 17344865
[No Abstract] [Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
Drucker DJ
Diabetes Care; 2007 Jun; 30(6):1335-43. PubMed ID: 17337495
[No Abstract] [Full Text] [Related]
14. Treatment of type 2 diabetes mellitus and the incretin system.
Whitehill D
S D Med; 2007 May; 60(5):197, 199. PubMed ID: 17694940
[No Abstract] [Full Text] [Related]
15. New treatment for diabetes.
FDA Consum; 2007; 41(1):3. PubMed ID: 17342826
[No Abstract] [Full Text] [Related]
16. Sitagliptin: a viewpoint by Mark S. Kipnes.
Kipnes MS
Drugs; 2007; 67(4):598-9. PubMed ID: 17352517
[No Abstract] [Full Text] [Related]
17. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
18. Sitagliptin/metformin (Janumet) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377
[No Abstract] [Full Text] [Related]
19. [Sitagliptin].
Taéron C
Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
[No Abstract] [Full Text] [Related]
20. [Sitagliptine (Januvia)].
Duh D; Vandevijver A
J Pharm Belg; 2008 Mar; 63(1):31-2. PubMed ID: 18479082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
